GlobeNewswire: AREVA Med Contains the last 10 of 15 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T12:06:33ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2018/02/20/1362056/0/en/Orano-Med-and-RadioMedix-announce-dosing-of-first-patients-in-AlphaMedix-Phase-1-clinical-trial.html?f=22&fvtc=4&fvtv=13659Orano Med and RadioMedix announce dosing of first patients in AlphaMedix™ Phase 1 clinical trial2018-02-20T15:09:28Z<![CDATA[COURBEVOIE, France and HOUSTON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Orano Med (formerly AREVA Med) and RadioMedix announced today the dosing of the first three patients in the AlphaMedix™ Phase 1 clinical trial. The objective of this Phase 1 is to determine safety, bio-distribution, and preliminary effectiveness of AlphaMedix™ in patients with somatostatin receptor positive neuroendocrine tumors (NETs).]]>https://www.globenewswire.com/news-release/2016/04/14/828924/0/ja/%E3%82%A2%E3%83%AC%E3%83%90-%E3%83%A1%E3%83%89-%E6%96%B0%E3%81%97%E3%81%84%E9%89%9B212%E7%94%9F%E7%94%A3%E6%96%BD%E8%A8%AD%E3%82%92%E9%96%8B%E8%A8%AD.html?f=22&fvtc=4&fvtv=13659アレバ・メド、新しい鉛212生産施設を開設2016-04-14T13:18:34Z<![CDATA[プレイノ市長ハリー・ラロジリェール (Harry LaRosiliere)、アレバ・メドCEOパトリック・ボーデ (Patrick Bourdet) 写真撮影:ジム・ハーンドン (Jim Herndon) プレイノ市長ハリー・ラロジリェール (Harry LaRosiliere)、アレバ・メドCEOパトリック・ボーデ (Patrick Bourdet) 写真撮影:ジム・ハーンドン (Jim Herndon) ]]>https://www.globenewswire.com/news-release/2016/04/13/828640/0/en/AREVA-Med-Inaugurates-Second-Lead-212-Production-Facility.html?f=22&fvtc=4&fvtv=13659AREVA Med Inaugurates Second Lead-212 Production Facility2016-04-13T19:22:42Z<![CDATA[PLANO, Texas, April 13, 2016 (GLOBE NEWSWIRE) -- AREVA Med has launched operations at its second high-purity lead-212 (212Pb) production facility located in Plano, Texas. Known as the DDPU (Domestic Distribution and Purification Unit), this facility was officially opened today in the presence of local elected officials, AREVA Med Scientific Advisory Committee, as well as AREVA Group and AREVA Med executives and teams from both the U.S. and France.]]>Harry LaRosiliere, mayor of Plano; Patrick Bourdet, AREVA Med CEO photo credit: Jim HerndonHarry LaRosiliere.jpghttps://www.globenewswire.com/news-release/2016/03/31/824740/0/en/Morphotek-and-AREVA-Med-to-collaborate-on-Lead-212-Targeted-Alpha-Therapies.html?f=22&fvtc=4&fvtv=13659Morphotek and AREVA Med to collaborate on Lead-212 Targeted Alpha Therapies 2016-03-31T16:00:00Z<![CDATA[EXTON, Pa. and COURBEVOIE, France, March 31, 2016 (GLOBE NEWSWIRE) -- Morphotek®, Inc., a subsidiary of Eisai Inc., and AREVA Med, the AREVA Group medical subsidiary developing innovative therapies to fight cancer, announced today that they have entered into a collaborative project to assess the potential of a novel alpha radio-immunotherapy treatment in the fight against cancer.]]>https://www.globenewswire.com/news-release/2016/02/29/815432/0/en/AREVA-Med-Partners-With-Art-Institute-of-Dallas-U-S-and-%C3%89cole-Sup%C3%A9rieure-de-Design-Troyes-France.html?f=22&fvtc=4&fvtv=13659AREVA Med Partners With Art Institute of Dallas (U.S.) and École Supérieure de Design Troyes (France)2016-02-29T18:30:00Z<![CDATA[PLANO, Texas, Feb. 29, 2016 (GLOBE NEWSWIRE) -- AREVA Med, with roots in France and the U.S., has selected two top design schools – French École Supérieure de Design Troyes and U.S. Art Institute Dallas Texas – to work on key elements of its new high-purity lead-212 (212Pb) production facility under construction in Plano, Texas.  ]]>https://www.globenewswire.com/news-release/2016/01/21/803744/0/en/AREVA-Med-s-Second-Production-Facility-on-Schedule-to-Open-in-2nd-Quarter-of-2016.html?f=22&fvtc=4&fvtv=13659AREVA Med’s Second Production Facility on Schedule to Open in 2nd Quarter of 20162016-01-21T17:48:04Z<![CDATA[PLANO, Texas, Jan. 21, 2016 (GLOBE NEWSWIRE) -- AREVA Med’s second high-purity lead-212 (212Pb) production facility is now well advanced in the construction and is expected to be operational, as scheduled, in the second quarter of 2016. Construction work began in September 2015 for this facility, known as the DDPU (Domestic Distribution and Purification Unit), which is located in Plano, Texas.]]>AREVA Med’s Domestic Distribution and Purification Unit, Plano, TexasAREVA Med’s Domestic Distribution and Purification Unit, Plano, Texashttps://www.globenewswire.com/news-release/2015/09/10/767542/10148983/en/AREVA-Med-Launches-Construction-in-the-U-S-of-Second-Facility-to-Produce-Lead-212-Used-for-Developing-Cancer-Treatments.html?f=22&fvtc=4&fvtv=13659AREVA Med Launches Construction in the U.S. of Second Facility to Produce Lead-212 Used for Developing Cancer Treatments2015-09-10T17:05:18Z<![CDATA[PLANO, Texas, Sept. 10, 2015 (GLOBE NEWSWIRE) -- AREVA Med has begun construction of the company's second lead-212 production facility, known as DDPU (Domestic Distribution and Purification Unit), located in Plano, Texas. The DDPU will become the AREVA Med U.S. headquarters and will also host the laboratories and offices of its subsidiary, Macrocyclics, the global leader in design and manufacturing of chelating agents and high-quality chemicals for nuclear medicine.]]>https://www.globenewswire.com/news-release/2015/05/18/736758/10134316/en/AREVA-Med-and-RadioMedix-Partner-to-Develop-New-Treatment-Against-Neuroendocrine-Tumors.html?f=22&fvtc=4&fvtv=13659AREVA Med and RadioMedix Partner to Develop New Treatment Against Neuroendocrine Tumors2015-05-18T13:00:00Z<![CDATA[Targeted Alpha Therapy with Lead-212 HOUSTON and BETHESDA, Md., May 18, 2015 (GLOBE NEWSWIRE) -- RadioMedix, a clinical phase biotechnology company focused in the development of radiopharmaceuticals for targeted diagnosis and therapy of cancer, and AREVA Med, the AREVA medical subsidiary developing innovative therapies to fight cancer, announced today that they have entered into an agreement to co-develop a novel treatment against neuroendocrine tumors (NETs) using Targeted Alpha Therapy with lead-212 (]]>https://www.globenewswire.com/news-release/2014/11/03/679052/10105456/en/AREVA-Med-to-Expand-Production-Capacities-in-the-U-S.html?f=22&fvtc=4&fvtv=13659AREVA Med to Expand Production Capacities in the U.S.2014-11-03T13:00:00Z<![CDATA[BETHESDA, Md., Nov. 3, 2014 (GLOBE NEWSWIRE) -- AREVA Med announced today plans to build a new production facility in the United States. The company has acquired land in Plano, Texas, for the future site of a new facility for lead-212 production for use in medical applications. This site will also serve as the new offices and laboratory for AREVA Med's subsidiary Macrocyclics, Inc., the global leader of chelating agent technology.]]>https://www.globenewswire.com/news-release/2014/04/01/623424/10074925/en/AREVA-Med-Phase-1-Clinical-Trial-Expanded-in-U-S.html?f=22&fvtc=4&fvtv=13659AREVA Med Phase 1 Clinical Trial Expanded in U.S.2014-04-01T13:52:49Z<![CDATA[Now Recruiting Patients in San Diego, California BETHESDA, Md., April 1, 2014 (GLOBE NEWSWIRE) -- AREVA Med announced today the expansion of its Phase 1 clinical trial through collaboration with University of California San Diego Moores Cancer Center. Eligible patients with abdominal cancers will now be able to enroll in AREVA Med's clinical trial at UC San Diego.]]>